VivoSeq
Oncology

Recurrent Anaplastic Large Cell Lymphoma

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Recurrent Anaplastic Large Cell Lymphoma is an early-stage landscape with 3 programs across 2 companies. The most active players are Acrotech Biopharma Inc., Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Acrotech Biopharma Inc.

2 programs

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma
Not yet recruiting·CCity of Hope Medical Center·Phase 1·NCT07691450·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)